Suppr超能文献

疫苗效力测量中替代动物使用的替代、减少和优化方案。

Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.

作者信息

Hendriksen Coenraad F M

机构信息

Netherlands Vaccine Institute, PO 11, 3720AL Bilthoven, The Netherlands.

出版信息

Expert Rev Vaccines. 2009 Mar;8(3):313-22. doi: 10.1586/14760584.8.3.313.

Abstract

Models to measure potency in vaccine research and development and preclinical testing are frequently based on an immunization-challenge procedure in laboratory animals. These models have proven to be very instrumental in scientifically underpinning the correlation of protection of selected vaccine antigens and their efficacy. In vivo models in vaccine research and development are, for the time being, irreplaceable, although significant progress has been made in using in vitro prescreening tests to evaluate particular immunological parameters. For a long time, in vivo potency tests have been similarly relevant for routine vaccine lot-release testing. The design of a potency test, defined in most pharmacopeias, relied on a direct or indirect-challenge procedure in laboratory animals. For various reasons, there now is an increased interest in the development of alternatives to the current in vivo potency tests. Animal models have their limitations, with respect to their relevance, reliability, costs and moral acceptability. All alternative approaches have in common that they ultimately result in a refinement, reduction or replacement in the use of animals. The new models range from modifications of the existing in vivo test procedure (e.g., use of humane end points or serology instead of challenge) to in vitro antigen-quantification tests. A new paradigm in quality control of vaccines is the consistency approach. This approach is state-of-the-art in quality control of the new-generation vaccines and it is now finding its way into the quality control of traditional vaccines. The consistency approach implies the use of a set of parameters to constitute a product profile, which is monitored throughout production, and which guarantees that each lot released is similar to a manufacturer-specific vaccine of proven clinical efficacy and safety. Consistency relies heavily on the implementation of quality systems, such as good manufacturing practice and quality assurance, and on the use of in vitro analytical tools, such as immunochemical and physicochemical tests.

摘要

用于衡量疫苗研发和临床前测试效力的模型通常基于实验室动物的免疫接种-攻毒程序。这些模型已被证明在科学地支持所选疫苗抗原的保护作用与其效力之间的相关性方面非常有用。尽管在使用体外预筛选试验评估特定免疫参数方面取得了重大进展,但疫苗研发中的体内模型目前仍不可替代。长期以来,体内效力测试在常规疫苗批放行测试中同样具有相关性。大多数药典中定义的效力测试设计依赖于实验室动物的直接或间接攻毒程序。由于各种原因,目前人们对开发替代当前体内效力测试的方法越来越感兴趣。动物模型在相关性、可靠性、成本和道德可接受性方面存在局限性。所有替代方法的共同之处在于,它们最终都会导致动物使用的优化、减少或替代。新模型的范围从对现有体内测试程序的修改(例如,使用人道终点或血清学替代攻毒)到体外抗原定量测试。疫苗质量控制的一种新范式是一致性方法。这种方法是新一代疫苗质量控制的最新技术,现在正进入传统疫苗的质量控制领域。一致性方法意味着使用一组参数来构成产品概况,在整个生产过程中对其进行监测,并确保每批放行的产品都与具有已证实临床疗效和安全性的特定制造商疫苗相似。一致性在很大程度上依赖于质量体系的实施,如良好生产规范和质量保证,以及体外分析工具的使用,如免疫化学和物理化学测试。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验